179 related articles for article (PubMed ID: 36850003)
21. Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis.
Piancone F; Saresella M; Marventano I; La Rosa F; Santangelo MA; Caputo D; Mendozzi L; Rovaris M; Clerici M
Front Immunol; 2018; 9():983. PubMed ID: 29780394
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
Chen JS; Wang MX; Wang MM; Zhang YK; Guo X; Chen YY; Zhang MQ; Sun JY; Liu YF; Liu C
Eur J Med Chem; 2022 Jul; 237():114379. PubMed ID: 35468514
[TBL] [Abstract][Full Text] [Related]
23. Increased Systolic Blood Pressure Mediates the Relationship Between Urate and Gout Risk in Indonesia: A Novel Application of a Partial Least Squares-Structural Equation Model.
Dyah Kurniasari M; Karwur FF; Rayanti RE; Huruta AD; Lin YH; Weng SF; Tsai HT
Biol Res Nurs; 2022 Jan; 24(1):40-47. PubMed ID: 34340595
[TBL] [Abstract][Full Text] [Related]
24. Precipitation of Soluble Uric Acid Is Necessary for
Alberts BM; Barber JS; Sacre SM; Davies KA; Ghezzi P; Mullen LM
J Rheumatol; 2019 Sep; 46(9):1141-1150. PubMed ID: 30824640
[TBL] [Abstract][Full Text] [Related]
25. Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals.
Dalbeth N; Pool B; Shaw OM; Harper JL; Tan P; Franklin C; House ME; Cornish J; Naot D
Ann Rheum Dis; 2015 Apr; 74(4):786-90. PubMed ID: 25646371
[TBL] [Abstract][Full Text] [Related]
26. Effect of Berberine on Activation of TLR4-NFκB Signaling Pathway and NLRP3 Inflammasome in Patients with Gout.
Dang WT; Xu D; Zhou JG
Chin J Integr Med; 2023 Jan; 29(1):10-18. PubMed ID: 36125615
[TBL] [Abstract][Full Text] [Related]
27. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
28. Increased Metallothionein-1 Associated with Gout Activity and Tophi.
Ma Y; Yin Z; Dai H; Wu D; Cong J; Huang X; Chen X; Zou L; Ye Z; Huang Z
Immunol Invest; 2023 Apr; 52(3):319-331. PubMed ID: 36719801
[TBL] [Abstract][Full Text] [Related]
29. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
Alghamdi YS; Soliman MM; Nassan MA
BMC Pharmacol Toxicol; 2020 Feb; 21(1):10. PubMed ID: 32041665
[TBL] [Abstract][Full Text] [Related]
30. The biology of urate.
Keenan RT
Semin Arthritis Rheum; 2020 Jun; 50(3S):S2-S10. PubMed ID: 32620198
[TBL] [Abstract][Full Text] [Related]
31. Levels of Cytokines and MicroRNAs in Individuals With Asymptomatic Hyperuricemia and Ultrasonographic Findings of Gout: A Bench-to-Bedside Approach.
Estevez-Garcia IO; Gallegos-Nava S; Vera-Pérez E; Silveira LH; Ventura-Ríos L; Vancini G; Hernández-Díaz C; Sánchez-Muñoz F; Ballinas-Verdugo MA; Gutierrez M; Pineda C; Rodriguez-Henriquez P; Castillo-Martínez D; Amezcua-Guerra LM
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1814-1821. PubMed ID: 29457379
[TBL] [Abstract][Full Text] [Related]
32. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.
Cleophas MC; Crişan TO; Lemmers H; Toenhake-Dijkstra H; Fossati G; Jansen TL; Dinarello CA; Netea MG; Joosten LA
Ann Rheum Dis; 2016 Mar; 75(3):593-600. PubMed ID: 25589513
[TBL] [Abstract][Full Text] [Related]
33. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
[No Abstract] [Full Text] [Related]
34. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack.
Lee JS; Kwon OC; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
Korean J Intern Med; 2020 Jan; 35(1):240-248. PubMed ID: 30685959
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
[TBL] [Abstract][Full Text] [Related]
37. Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout.
Fatima T; Altaf S; Phipps-Green A; Topless R; Flynn TJ; Stamp LK; Dalbeth N; Merriman TR
Rheumatol Int; 2016 Feb; 36(2):255-61. PubMed ID: 26410617
[TBL] [Abstract][Full Text] [Related]
38. The genetic basis of gout.
Merriman TR; Choi HK; Dalbeth N
Rheum Dis Clin North Am; 2014 May; 40(2):279-90. PubMed ID: 24703347
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.
Liu N; Xu L; Shi Y; Fang L; Gu H; Wang H; Ding X; Zhuang S
Oncotarget; 2017 May; 8(20):33807-33826. PubMed ID: 28442634
[TBL] [Abstract][Full Text] [Related]
40. Fingolimod Phosphate (FTY720-P) Activates Protein Phosphatase 2A in Human Monocytes and Inhibits Monosodium Urate Crystal-Induced Interleukin-1
Qadri M; ElSayed S; Elsaid KA
J Pharmacol Exp Ther; 2021 Feb; 376(2):222-230. PubMed ID: 33239408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
